Weight Loss & MetabolicPeer Reviewed
Reasons for Discontinuation of Obesity Pharmacotherapy With Semaglutide or Tirzepatide in Clinical Practice.
Authors (10)
Hamlet Gasoyan
W Scott Butsch
Nicholas J CasacchiaCenter for Value-Based Care Research, Department of Internal Medicine and Geriatrics, Primary Care Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Rebecca SchulteDepartment of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, USA.
Obesity (Silver Spring, Md.)
Unknown
Published
Oct 13, 2025
Abstract
Abstract not available - data parsing issue resolved
Keywords
glucagon‐like peptide‐1 receptor agonistsobesity pharmacotherapytreatment discontinuation
Article Metrics
Sourcepubmed
Related Research
Explore more articles in this research category to discover related studies and findings.